Top

Published in:

Open Access 01-10-2019 | NSCLC | Review

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

Authors: Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Nadia Barraco, Marco Bono, Lidia Rita Corsini, Antonio Galvano, Valerio Gristina, Angela Listì, Salvatore Vieni, Stefania Gori, Viviana Bazan, Antonio Russo

Published in: Advances in Therapy | Issue 10/2019

Abstract

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1 (PD-L1) antibodies, showing, in several cancer patients, an increased progression-free survival and overall survival compared with classical chemotherapy. As recently shown by several studies, the PD-L1 expression levels in tumors may offer a selection criterion for patients to predict their immunotherapy response. In particular, NSCLC patients with high tumor PD-L1 levels (proportional score ≥ 50% for first-line therapy and ≥ 1% for second-line treatment, respectively) showed better response rates to immunotherapy and longer survival in first-line therapy compared with conventional chemotherapy. PD-L1, whose expression is evaluated by using immunohistochemistry analysis, is currently the only biomarker approved for clinical use in the first- and second-line monotherapy setting and therefore plays a central role in treatment decision-making for patients with advanced NSCLC. In this review we will discuss the key role of PD-L1 as a predictive biomarker of response to pembrolizumab therapy in NSCLC patients by describing the appropriate techniques and methodologies for immunohistochemical evaluation of PD-L1 expression and providing an overview of the clinical studies supporting its predictive significance.

Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2015;13(3):143–58. https://doi.org/10.1038/nrclinonc.2015.209.CrossRefPubMed

Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015. https://doi.org/10.18632/oncotarget.3204.CrossRefPubMed

Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–72. https://doi.org/10.1038/nrc3973.CrossRefPubMed

Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology. 2015;145(2):182–201. https://doi.org/10.1111/imm.12459.CrossRefPubMedPubMedCentral

He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015. https://doi.org/10.1038/srep13110.CrossRefPubMedPubMedCentral

Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410–6. https://doi.org/10.7150/jca.17144.CrossRefPubMedPubMedCentral

Incorvaia L, Bronte G, Bazan V, Badalamenti G, Rizzo S, Pantuso G, et al. Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.7267.CrossRefPubMedPubMedCentral

Camisaschi C, Vallacchi V, Castelli C, Rivoltini L, Rodolfo M. Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Expert Rev Mol Diagn. 2014;14(6):643–6. https://doi.org/10.1586/14737159.2014.928206.CrossRefPubMed

Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42. https://doi.org/10.1038/nri3405.CrossRefPubMedPubMedCentral

10.

Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22(3):333–40. https://doi.org/10.1016/j.coi.2010.02.013.CrossRefPubMedPubMedCentral

11.

Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. OncoImmunology. 2014;1(8):1223–5. https://doi.org/10.4161/onci.21335.CrossRef

12.

Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol. 2018. https://doi.org/10.1016/j.cellimm.2018.01.013.CrossRefPubMed

13.

Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2014;21(4):687–92. https://doi.org/10.1158/1078-0432.ccr-14-1860.CrossRefPubMedPubMedCentral

14.

Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig. 2015;125(9):3384–91. https://doi.org/10.1172/jci80011.CrossRefPubMedPubMedCentral

15.

Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229(1):114–25. https://doi.org/10.1111/j.1600-065X.2009.00767.x.CrossRefPubMedPubMedCentral

16.

Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–53. https://doi.org/10.1128/mcb.25.21.9543-9553.2005.CrossRefPubMedPubMedCentral

17.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMoa1412082.CrossRefPubMed

18.

Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84. https://doi.org/10.1016/s1470-2045(15)70076-8.CrossRefPubMed

19.

Guo Y, Wang AY. Novel immune check-point regulators in tolerance maintenance. Front Immunol. 2015. https://doi.org/10.3389/fimmu.2015.00421.CrossRefPubMedPubMedCentral

20.

Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–13. https://doi.org/10.1016/j.coi.2006.01.011.CrossRefPubMed

21.

Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501–9. https://doi.org/10.1038/bjc.2015.101.CrossRefPubMedPubMedCentral

22.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930–40. https://doi.org/10.1172/jci91190.CrossRefPubMedPubMedCentral

23.

Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56. https://doi.org/10.1158/1535-7163.mct-14-0983.CrossRefPubMed

24.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.CrossRefPubMed

25.

Corsini LR, Fanale D, Passiglia F, Incorvaia L, Gennusa V, Bazan V, et al. Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opin Drug Saf. 2018;17(12):1197–209. https://doi.org/10.1080/14740338.2018.1550068.CrossRefPubMed

26.

Passiglia F, Galvano A, Rizzo S, Incorvaia L, Listì A, Bazan V, et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. 2018;142(6):1277–84. https://doi.org/10.1002/ijc.31136.CrossRefPubMed

27.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. https://doi.org/10.1056/NEJMoa1709684.CrossRefPubMedPubMedCentral

28.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMedPubMedCentral

29.

Cavanna L, Citterio C, Orlandi E. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget. 2018. https://doi.org/10.18632/oncotarget.26541.CrossRefPubMedPubMedCentral

30.

Robert C, Long GV, Schachter J, Arance A, Grob JJ, Mortier L, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. J Clin Oncol. 2017;35(15_suppl):9504. https://doi.org/10.1200/jco.2017.35.15_suppl.9504.CrossRef

31.

Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien A-S, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. OncoImmunology. 2019;8(4):e1561120. https://doi.org/10.1080/2162402x.2018.1561120.CrossRefPubMedPubMedCentral

32.

Teixidó C, Vilariño N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol. 2018;10:175883591876349. https://doi.org/10.1177/1758835918763493.CrossRef

33.

Scheel AH, Schäfer SC. Current PD-L1 immunohistochemistry for non-small cell lung cancer. J Thorac Dis. 2018;10(3):1217–9. https://doi.org/10.21037/jtd.2018.02.38.CrossRefPubMedPubMedCentral

34.

Sui H, Ma N, Wang Y, Li H, Liu X, Su Y, et al. Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer: toward personalized medicine and combination strategies. J Immunol Res. 2018;2018:1–17. https://doi.org/10.1155/2018/6984948.CrossRef

35.

Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24(6):392–7. https://doi.org/10.1097/pai.0000000000000408.CrossRefPubMedPubMedCentral

36.

Thunnissen E, de Langen AJ, Smit EF. PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer. 2017;113:102–5. https://doi.org/10.1016/j.lungcan.2017.09.010.CrossRefPubMed

37.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824.CrossRefPubMed

38.

Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/s0140-6736(15)01281-7.CrossRefPubMed

39.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Ann Oncol. 2019;30(2):281–9. https://doi.org/10.1093/annonc/mdy545.CrossRefPubMedPubMedCentral

40.

Russo A, Franchina T, Ricciardi GRR, Toscano G, Schifano S, Lo Certo G, et al. The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. Crit Rev Oncol Hematol. 2018;130:1–12. https://doi.org/10.1016/j.critrevonc.2018.06.007.CrossRefPubMed

41.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 Tumor Proportion Score of 50% or greater. J Clin Oncol. 2019;37(7):537–46. https://doi.org/10.1200/jco.18.00149.CrossRefPubMed

42.

Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2019;393(10183):1819–30. https://doi.org/10.1016/s0140-6736(18)32409-7.CrossRef

43.

Karim S, Leighl N. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. Future Oncol. 2016;12(1):9–23. https://doi.org/10.2217/fon.15.294.CrossRefPubMed

44.

Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, et al. PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol. 2016;9(1):64–9. https://doi.org/10.1016/j.tranon.2016.01.003.CrossRefPubMedPubMedCentral

45.

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways. Am J Clin Oncol. 2016;39(1):98–106. https://doi.org/10.1097/coc.0000000000000239.CrossRefPubMedPubMedCentral

46.

Ilie M, Hofman V, Dietel M, Soria J-C, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468(5):511–25. https://doi.org/10.1007/s00428-016-1910-4.CrossRefPubMed

47.

Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. 24-Month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2019;14(1):124–9. https://doi.org/10.1016/j.jtho.2018.08.004.CrossRefPubMed

48.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005.CrossRefPubMed

49.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.CrossRefPubMed

50.

Zhang Y, Wang L, Li Y, Pan Y, Hu H, Li H, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. OncoTargets Ther. 2014. https://doi.org/10.2147/ott.s59959.CrossRef

51.

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–53. https://doi.org/10.1093/annonc/mdv489.CrossRefPubMed

52.

Dolled-Filhart M, Locke D, Murphy T, Lynch F, Yearley JH, Frisman D, et al. Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch Pathol Lab Med. 2016;140(11):1259–66. https://doi.org/10.5858/arpa.2015-0544-OA.CrossRefPubMed

53.

Mino-Kenudson M, Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med. 2016;13(2):157–70. https://doi.org/10.20892/j.issn.2095-3941.2016.0009.CrossRefPubMedPubMedCentral

54.

Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017;35(34):3867–76. https://doi.org/10.1200/jco.2017.74.7642.CrossRefPubMed

55.

Dolled-Filhart M, Roach C, Toland G, Stanforth D, Jansson M, Lubiniecki GM, et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med. 2016;140(11):1243–9. https://doi.org/10.5858/arpa.2015-0542-OA.CrossRefPubMed

56.

Novotny JF, Cogswell J, Inzunza H, Harbison C, Horak C, Averbuch S. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Ann Oncol. 2016;27(10):1966–9. https://doi.org/10.1093/annonc/mdw288.CrossRefPubMedPubMedCentral

57.

Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208–22. https://doi.org/10.1016/j.jtho.2016.11.2228.CrossRefPubMed

58.

Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302–11. https://doi.org/10.1016/j.jtho.2018.05.013.CrossRefPubMedPubMedCentral

59.

Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, et al. Comparison of 22C3 PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer. J Thorac Oncol. 2017;12(10):1536–43. https://doi.org/10.1016/j.jtho.2017.07.015.CrossRefPubMed

60.

Skov BG, Skov T. Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol. 2017;25(7):453–9. https://doi.org/10.1097/pai.0000000000000540.CrossRefPubMed

61.

Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, et al. PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017;125(12):896–907. https://doi.org/10.1002/cncy.21937.CrossRefPubMed

62.

Wang H, Spatz A. Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC. Oncotarget. 2018. https://doi.org/10.18632/oncotarget.26261.CrossRefPubMedPubMedCentral

63.

Midha A, Sharpe A, Scott M, Walker J, Shi K, Ballas M, et al. PD-L1 expression in advanced NSCLC: primary lesions versus metastatic sites and impact of sample age. J Clin Oncol. 2016;34(15_suppl):3025. https://doi.org/10.1200/jco.2016.34.15_suppl.3025.CrossRef

64.

Kerr KM, Hirsch FR. Programmed death ligand-1 immunohistochemistry: friend or foe? Arch Pathol Lab Med. 2016;140(4):326–31. https://doi.org/10.5858/arpa.2015-0522-SA.CrossRefPubMed

65.

Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 2016;69(2):177–86. https://doi.org/10.1111/his.12996.CrossRefPubMed

66.

Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239–45. https://doi.org/10.1038/ni1443.CrossRefPubMed

67.

Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11(7):964–75. https://doi.org/10.1016/j.jtho.2016.04.014.CrossRefPubMedPubMedCentral

68.

Garon EB. Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol. 2015;42:S11–8. https://doi.org/10.1053/j.seminoncol.2015.09.019.CrossRefPubMed

69.

Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28(4):874–81. https://doi.org/10.1093/annonc/mdx008.CrossRefPubMedPubMedCentral

70.

Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–7. https://doi.org/10.5858/arpa.2018-0043-OA.CrossRefPubMed

71.

Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–24. https://doi.org/10.1016/s0140-6736(16)31473-8.CrossRefPubMed

72.

Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29(4):953–8. https://doi.org/10.1093/annonc/mdy014.CrossRefPubMed

73.

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;29(10):1165–72. https://doi.org/10.1038/modpathol.2016.117.CrossRefPubMed

74.

Lin F, Chen Z. Standardization of diagnostic immunohistochemistry: literature review and geisinger experience. Arch Pathol Lab Med. 2014;138(12):1564–77. https://doi.org/10.5858/arpa.2014-0074-RA.CrossRefPubMed

75.

Vyberg M, Nielsen S. Proficiency testing in immunohistochemistry—experiences from nordic immunohistochemical quality control (NordiQC). Virchows Arch. 2015;468(1):19–29. https://doi.org/10.1007/s00428-015-1829-1.CrossRefPubMedPubMedCentral

76.

Ibrahim M, Parry S, Wilkinson D, Bilbe N, Allen D, Forrest S, et al. ALK immunohistochemistry in NSCLC: discordant staining can impact patient treatment regimen. J Thorac Oncol. 2016;11(12):2241–7. https://doi.org/10.1016/j.jtho.2016.07.012.CrossRefPubMed

Title: Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Authors: Lorena Incorvaia
Daniele Fanale
Giuseppe Badalamenti
Nadia Barraco
Marco Bono
Lidia Rita Corsini
Antonio Galvano
Valerio Gristina
Angela Listì
Salvatore Vieni
Stefania Gori
Viviana Bazan
Antonio Russo
Publication date: 01-10-2019
Publisher: Springer Healthcare
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
Lung Cancer
Biomarkers
Checkpoint Inhibitors
Cytostatic Therapy
Published in: Advances in Therapy / Issue 10/2019
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-019-01057-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2019

Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients

Exploration of Different Rehabilitation Routes for Sepsis Survivors with Monitoring of Health Status and Quality of Life: RehaSep Trial Protocol

Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally

Thyroid Surgery: Whose Domain Is It?

Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia

Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page